---
title: "Ensysce Biosciences rises 9% after-hours on Cy Biopharma acquisition and CRPS pipeline expansion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295146288.md"
description: "Ensysce Biosciences rose 9% after-hours after completing the Cy Biopharma acquisition and securing the CRPS candidate CY200."
datetime: "2026-08-06T21:25:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295146288.md)
  - [en](https://longbridge.com/en/news/295146288.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295146288.md)
---

# Ensysce Biosciences rises 9% after-hours on Cy Biopharma acquisition and CRPS pipeline expansion

Ensysce Biosciences(ENSC.US) 盘后时段涨近 9%，现报 0.5549 美元。

公司已完成对 Cy Biopharma 的收购，获得复杂区域疼痛综合征 (CRPS) 临床阶段候选药物 CY200。交易包含**1710 万美元**现金，并同步进行目标**2150 万美元**毛收入的定向增发，另有**3860 万美元**后续融资与临床里程碑挂钩。资金将支持该药物至**2028 年**的第二阶段开发及注册准备。

此外，Ensysce Biosciences 发布了投资者演示文件，重点介绍其胰蛋白酶控制阿片类药物平台 TAAP 和 MPAR，以及疼痛管线的研发进展。该公司一款 TAAP 氢可酮产品已于**2024 年 1 月**获得 FDA 突破性疗法认定。

### Related Stocks

- [ENSC.US](https://longbridge.com/en/quote/ENSC.US.md)

## Related News & Research

- [Ensysce Biosciences Q2 net loss widens on higher R&D costs](https://longbridge.com/en/news/295841617.md)
- [Ensysce Biosciences posts investor presentation spotlighting trypsin-controlled opioid platforms, pain pipeline](https://longbridge.com/en/news/295107304.md)
- [Ensysce Biosciences completes Cy Biopharma acquisition](https://longbridge.com/en/news/295106106.md)
- [Ensysce enrolls first patient in final phase of PF614-MPAR-102 overdose-protection trial](https://longbridge.com/en/news/290962389.md)
- [Ensysce Biosciences GAAP EPS of -$0.52 beats by $0.21](https://longbridge.com/en/news/286613093.md)